Citadel Advisors »

Rapport Therapeutics shares owned by Citadel Advisors

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2024-09-30 $9.5M 488k 19.46
2024-06-30 $13M 593k 22.30

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit Call Option (SPY)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
NVIDIA Corporation Call Option (NVDA)
Tesla Motors Call Option (TSLA)
Apple Call Option (AAPL)
Ishares Tr Russell 2000 Etf Call Option (IWM)
Meta Platforms Cl A Call Option (META)
Microsoft Corporation Call Option (MSFT)
Amazon Call Option (AMZN)
Advanced Micro Devices Call Option (AMD)
Broadcom Call Option (AVGO)
Netflix Call Option (NFLX)
Alphabet Cap Stk Cl A Call Option (GOOGL)
Booking Holdings Call Option (BKNG)
Spdr Gold Tr Gold Shs Call Option (GLD)

View all positions for Citadel Advisors

Top funds holding Rapport Therapeutics

Arch Venture Corp
Cormorant Asset Management
Capital Research and Management Company - Division 3
Johnson & Johnson
Sofinnova Ventures
T. Rowe Price Investment Management
Alliancebernstein
T. Rowe Price Associates
Perceptive Advisors
BlackRock
Citadel Advisors
Siren
Logos Global Management
Geode Capital Management
Woodline Partners

View all funds holding Rapport Therapeutics